Aveo Pharmaceuticals, Inc.

Tarveda Therapeutics, Inc.

Samantha Perino

Jeno Gyuris

William M Winston, Jr

Sandra Abbott

Alisa C Bell

Ronan O'Hagan

Heidi Okamura

Kelly Kreuter

Hamid Tissire

Mark T Bilodeau

Sudhakar Kadiyala

Rajesh R Shinde

Richard Wooster

Kerry Whalen

Beata Sweryda-Krawiec

Patrick Rosaire Bazinet

Monoclonal antibodies that bind and inhibit activation of human Notch3 are disclosed. The antibodies can be used to treat cell proliferative diseases and disorders, including certain forms of cancer, associated with activation of Notch3.

Anti-notch3 antibodies

Conjugates of an active agent such as DM1 attached to a targeting moiety, such as a somatostatin receptor binding moiety, via a linker, and particles comprising such conjugates have been designed. Such conjugates and particles can provide improved temporospatial delivery of the active agent, improved biodistribution and penetration in tumor, and/or decreased toxicity. Methods of making the conjugates, the particles, and the formulations thereof are provided. Methods of administering the formulations to a subject in need thereof are provided, for example, to treat or prevent cancer.

SSTR-targeted conjugates and particles and formulations thereof

Anti-NOTCH3 antibodies

Anti-Notch3 antibodies

Growing community of inventors

Brighton, MA, United States of America

Samantha Perino